Summary of HR 5139 - EPIPEN Act

Bill Overview

Bill Number: HR 5139

Title: EPIPEN Act

Status: Introduced in House

Introduced On: September 04, 2025

Classification: Bill

Purpose and Intent

The EPIPEN Act aims to address the accessibility and affordability of epinephrine auto-injectors, commonly known as EpiPens, which are critical for individuals experiencing severe allergic reactions (anaphylaxis). The legislation seeks to ensure that these life-saving devices are available to those who need them without prohibitive costs.

Key Provisions

While the specific text of the bill is not provided, the EPIPEN Act is expected to include the following key provisions:

• Price Regulation: Measures to regulate the pricing of EpiPens to prevent excessive costs that can limit access for patients.
• Insurance Coverage: Requirements for insurance companies to cover the cost of EpiPens without high out-of-pocket expenses for patients.
• Availability: Initiatives to increase the availability of EpiPens in schools, public places, and emergency services to ensure that individuals at risk have access when needed.

Affected Parties

The EPIPEN Act would primarily impact:

• Individuals with Allergies: Patients who require EpiPens for anaphylaxis treatment would benefit from improved access and affordability.
• Healthcare Providers: Medical professionals would have clearer guidelines on prescribing and providing EpiPens to patients.
• Insurance Companies: Insurers would need to adjust their policies to comply with the new regulations regarding coverage and pricing.

Legislative Process

• Referral to Committees: Upon introduction, the bill was referred to the Committee on Energy and Commerce, as well as the Committees on Education and Workforce, and Ways and Means. Each committee will review the bill's provisions relevant to their jurisdiction.
• Timeline: The timeline for further action on the bill will be determined by the Speaker of the House, indicating that additional hearings or discussions may occur before any votes are taken.

Sponsors

• Primary Sponsor: Maxwell Frost
• Cosponsor: Doris O. Matsui

Conclusion

The EPIPEN Act represents a significant legislative effort to improve the accessibility and affordability of EpiPens for individuals at risk of severe allergic reactions. As the bill progresses through the legislative process, it will be crucial to monitor its developments and the implications for patients and healthcare providers alike.